Evidence map›Paper›PMID 24260543›Full record

ArticlePloS one2013

Analysis of the tolerance to DNA alkylating damage in MEC1 and RAD53 checkpoint mutants of Saccharomyces cerevisiae.

Alfonso Gallego-Sánchez, Sandra Ufano, Sonia Andrés, Avelino Bueno

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.7field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 8 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Alfonso Gallego-SánchezInstituto de Biología Molecular y Celular del Cáncer, Departamento de Microbiología y Genética, Universidad de Salamanca/CSIC, Salamanca, Spain.
Sandra Ufano
Sonia Andrés
Avelino Bueno
Universidad de Salamanca · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Checkpoint response, tolerance and repair are three major pathways that eukaryotic cells evolved independently to maintain genome stability and integrity. Here, we studied the sensitivity to DNA damage in checkpoint-deficient budding yeast cells and found that checkpoint kinases Mec1 and Rad53 may modulate the balance between error-free and error-prone branches of the tolerance pathway. We have consistently observed that mutation of the RAD53 counterbalances error-free and error-prone branches upon exposure of cells to DNA damage induced either by MMS alkylation or by UV-radiation. We have also found that the potential Mec1/Rad53 balance modulation is independent from Rad6/Rad18-mediated PCNA ubiquitylation, as mec1Δ or rad53Δ mutants show no defects in the modification of the sliding clamp, therefore, we infer that it is likely exerted by acting on TLS polymerases and/or template switching targets.

Indexed as

Gene Expression Regulation, FungalAlkylating AgentsCell Cycle ProteinsCheckpoint Kinase 2DNA-Binding ProteinsDNA DamageIntracellular Signaling Peptides and ProteinsMethyl MethanesulfonateMutationProliferating Cell Nuclear AntigenProtein Serine-Threonine KinasesSaccharomyces cerevisiaeSaccharomyces cerevisiae ProteinsSignal TransductionUbiquitin-Conjugating EnzymesUltraviolet RaysAlkylating AgentsCell Cycle ProteinsCheckpoint Kinase 2DNA-Binding ProteinsIntracellular Signaling Peptides and ProteinsMEC1 protein, S cerevisiaeMethyl MethanesulfonateProliferating Cell Nuclear AntigenProtein Serine-Threonine KinasesRAD18 protein, S cerevisiaeRAD53 protein, S cerevisiaeRAD6 protein, S cerevisiaeSaccharomyces cerevisiae ProteinsUbiquitin-Conjugating Enzymes

Identifiers

PMID24260543
PMCPMC3834268
OpenAlexW2029850123

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.